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Abstract 19 
The relevant efficacy of monoclonal antibodies (mAbs) has resulted in the successful  20 
treatment of several diseases, although susceptibility to infections remains a major 21 
problem. This review summarizes aspects of the literature regarding viral infections and 22 
mAbs, specifically addressing the risk of infection/reactivation, the measures that can 23 
reduce this risk, and the role played by the laboratory of clinical virology in monitoring the 24 
patients undergoing mAb therapy. 25 
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Introduction 30 
The treatment of several medical conditions, such as cancer and autoimmune diseases, 31 
has been revolutionized following the introduction of biologic therapies targeting specific 32 
components of pathways involved in the pathogenic mechanisms. These agents are 33 
prevalently monoclonal antibodies (mAbs). Immunotherapy developed with the discovery 34 
of antibodies structure and the introduction of hybridoma technology, which provided the 35 
first source of mAbs [1]. Initially, murine mAbs (suffix –omab) were burdened by major 36 
problems due to immune complex formation and inadequate recruitment of host effector 37 
functions. To overcome this, murine molecules were engineered to remove immunogenic 38 
content and to increase the immunomodulant efficiency; this was achieved by the 39 
production of chimeric (composed of murine variable regions fused onto human constant 40 
regions, ~65% human component; suffix –ximab) and humanized (produced by grafting 41 
murine hypervariable aminoacid domain into human antibodies, ~95% human component; 42 
suffix –zumab) antibodies. Extensive researches are currently conducted to originate 43 
mAbs for several diseases, such as rheumatoid arthritis, multiple sclerosis, inflammatory 44 
bowel diseases, and many types of neoplasms. However, susceptibility to infections 45 
remains a major concern, as the target of these mAbs are molecules or cells involved in 46 
immune anti-infectious pathways. The severity of these infections can be influenced by the 47 
protocol utilized (dosage, frequency, and route of administration). Considering the most 48 
used mAbs in clinical practice, the reported infectious complications remain low and limit 49 
particularly the utilization of mAbs targeting antigens such as CD52, CD20, tumor necrosis 50 
factor (TNF)-α and the integrin very late antigen  (VLA)-4 [2]. Beside bacterial and fungal 51 
infections, viral infections/reactivations represent important factors limiting the utilization of 52 
biological agents (Table 1). 53 
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 54 
Anti-CD52: alemtuzumab 55 
Alemtuzumab is a humanized anti-CD52 antibody (Campath®), that is mainly expressed 56 
on the surface of peripheral B- and T-cells, both normal and malignant, monocytes, 57 
thymocytes, natural killer cells and macrophages, whereas it is not expressed on 58 
erythrocytes or platelets. This mechanism of action makes alemtuzumab indicated for the 59 
treatment of chronic lymphocytic leukemia, non-Hodgkin lymphomas, post-transplantation 60 
and graft-versus-host disease. Treatment results in lymphoid ablation. In this context,  61 
reactivation of cytomegalovirus (CMV) is an important problem, having been reported in 6-62 
66% of patients [3]. The wide range of reported incidence might be a result of differences 63 
in study design, population, and viral detection modes; moreover, earlier studies might 64 
have underreported the incidence of CMV reactivation, because CMV was not routinely 65 
monitored. Nevertheless, the benefit/risk ratio favors its utilization associated to a close 66 
virological monitoring for early detection of reactivation, as pre-emptive treatment prevents 67 
the occurrence of potentially life-threatening disease and the initiation of anti-CMV 68 
treatment avoids the interruption of alemtuzumab. Cytomegalovirus reactivation is typically 69 
observed between 4 and 6 weeks after the initiation of treatment [4]. Usually, given the 70 
high background of CMV-seropositivity, reactivation is monitored weekly by a sensitive 71 
detection method (CMV-DNAemia). In clinical trials, among the exclusion criteria for the 72 
recruitment, CMV-DNAemia positivity at screening makes the patient not eligible. 73 
Treatment to reduce viral load to a non-detectable level is required and study entry is 74 
possible once the infection has been treated. Among exclusion criteria, there are active or 75 
prior viral hepatitis B or C or positivity for hepatitis B serology. Patients with hepatitis B 76 
surface antibodies (HBsAb) with documented history of prior hepatitis B immunization are 77 
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eligible if other criteria are met (i.e. negativity for HBsAg, HBcAb, and anti-HCV). Patients 78 
with HIV-infection are excluded. In Figure 1, an algorithm for the evaluation of viral 79 
infections in relation to the administration of alemtuzumab is reported. 80 
 81 
Anti-CD20: rituximab 82 
Rituximab (Mabthera® or Rituxan®) is a chimeric mAb targeting the CD20 molecule, that 83 
is expressed on the normal B-cell lineage (from pre-B stage to memory stage) as well as 84 
on abnormal B-lymphocytes. Rituximab has been approved for the treatment of indolent 85 
CD20, B-cell non-Hodgkin lymphomas, and chronic lymphocytic leukemia, as well as for 86 
that of moderate-to-severe rheumatoid arthritis. Several viral infections related to rituximab 87 
have been reported. In a metanalysis [5], 64 cases of serious viral infection after rituximab 88 
treatment were found, in particular HBV reactivation in patients with chronic lymphocytic 89 
leukemia and lymphomas [5,6-9], followed by CMV, varicella-zoster virus, and others. A 90 
close monitoring for viral infections, particularly HBV and CMV, by molecular methods is 91 
recommended. Periodic monitoring of HBV-DNA may predict HBV reactivation, thus being 92 
advantageous in terms of costs; it is also essential in cases with HBV-DNA mutations and 93 
when antibody expression is weak. The identification of HBV reactivation at an early stage 94 
is important; therefore, in addition to HBV-DNA monitoring, it should be recommended to 95 
evaluate changes in anti-HB titers [10]. Viral reactivation of polyomavirus JC from sites of 96 
latency leading to the development of infection and destruction of the oligodendrocytes is 97 
the pathogenic mechanism responsible for progressive multifocal leukoencephalopathy 98 
(PML). To date, 57 PML cases have occurred in patients treated with rituximab [11,12]. A 99 
high degree of awareness for PML facilitates case identification; as a definitive diagnosis 100 
of PML is based on clinical, neuroimaging, histopathologic findings, as well as on the 101 
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detection of JCV in the brain tissue, less invasive methods based on the detection of JCV-102 
DNA in cerebrospinal fluid have been proposed. Evaluation of JCV-DNA on serum 103 
specimens seems to display low operating characteristics, given the rarity of PML and the 104 
high incidence of transient viremia (up to 18% in HIV-patients without PML)[13].  105 
 106 
Tumor necrosis factor-α antagonists 107 
Monoclonal antibodies that antagonize TNF-α (i.e. infliximab, etanercept, adalimumab, 108 
certolizumab pegol) are used for several inflammatory diseases, such as Crohn’s disease, 109 
rheumatoid polyarthritis, psoriasis, ankylosing spondylitis, and juvenile idiopathic arthritis. 110 
While the association with an increased risk of severe bacterial infections and reactivation 111 
of tuberculosis has been recognized, the impact on viral infections is less known. Long-112 
term safety and efficacy in patients with chronic HBV or HCV and/or HIV infection are 113 
poorly known. However, history or current active HBV, history of HCV and HIV infection 114 
are exclusion criteria for enrollment in clinical trials. As regards HCV, elevated levels of 115 
TNF-α are associated with chronic infection and there is a growing evidence that the 116 
pathogenesis of hepatocyte destruction may be mediated by the upregulation of 117 
inflammatory cytokines such as TNF-α. Therefore, TNF-α antagonists may be beneficial 118 
when used in cases of HCV [14,15] and there are some reports indicating that anti-TNF-α 119 
therapy in the setting of HCV appears to be safe. However, as the role of TNF-α is 120 
complex, the FDA points out the possible risk of reactivation of chronic viral hepatitis. 121 
Overall, data on safety and efficacy are conflicting; therefore, the presence of HCV should 122 
not be an absolute contraindication, given an appropriate pretreatment screening and a 123 
close monitoring. For selected patients, anti-TNF-α therapy in the setting of HCV appears 124 
to be safe without apparent influence on the underlying infection. Interval monitoring of 125 
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serum aminotransferases and HCV viral load is recommended. Elevated levels of TNF-α 126 
are also seen in patients with chronic HBV and, in these patients, it may play a role in 127 
clearing and controlling replication by synergizing with interferon; inhibition of TNF-α could 128 
theoretically lead to enhanced viral replication [16,17]. Reports of patients with chronic 129 
HBV who were treated with infliximab or etanercept, and developed a severe reactivation, 130 
sometimes with fulminant hepatitis, have been published [18-21]. In most cases, patients 131 
had chronic HBV with HBsAg positivity, but in others fulminant hepatitis was associated 132 
with a previously unrecognized HBsAg-carrier condition. For HBsAg-negative patients with 133 
a known history of HBV, the risk of reactivation is very low, but it cannot be totally 134 
excluded. Patients who are persistently HBsAg-negative, but have an occult HBV infection, 135 
have also been described. These patients may be at risk of developing a flare of hepatitis 136 
during the course of anti-TNF-α agents as this may interrupt the suppression of viral 137 
replication and gene expression typical for the occult HBV [17]. Evaluation of risk-benefit 138 
profile for specific antiviral treatment with lamivudine should be performed [17]. In 139 
conclusion, screening for HBV in all patients prior to treatment with anti-TNF-α agents 140 
should be recommended and, if treatment has been initiated, carriers of HBV should be 141 
closely monitored for laboratory and clinical signs of viral reactivation during therapy and 142 
for several months following its termination. 143 
Few data on the risk of reactivation of herpesvirus infections are available. Several cases 144 
of CMV infection have been reported, although severe clinical manifestations are rare. 145 
Authors suggested the assessment of CMV pp65-antigen levels or quantification of CMV-146 
DNA in symptomatic patients [22-26]. Limited informations are available on Epstein-Barr 147 
virus reactivation, as well as JCV. Large studies with long follow-up are needed to define 148 
the risk and opportunity for viral monitoring. Epstein-Barr virus is associated with 149 
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lymphoproliferative diseases in immunosuppressed patients and infliximab treatment has 150 
been resulted in transient elevations in viral load in some patients, although at levels lower 151 
than those associated to lymphoproliferative disorders [27]. Similarly, also limited data are 152 
available on varicella zoster virus and screening recommendations for the presence of 153 
antibodies prior to treatment or a prophylactic vaccination in non-immune patients remain 154 
questionable [28].  155 
Specific effects of anti-TNF-α therapy on human papillomavirus-associated diseases 156 
remain unknown, with very few reports suggesting a significantly increased risk in patients 157 
with inflammatory bowel diseases treated with infliximab [29]. 158 
HIV is considered among the relative contraindications for anti-TNF-α therapy, however its 159 
safety in HIV-infected patients is unknown. Their use should be reserved for highly 160 
selected patients, although further studies are needed. The potential impact of the loss of 161 
HIV control needs to be determined before establishing a clear recommendation; to 162 
promptly identify reactivation of HIV, close monitoring of clinical and laboratory parameters 163 
in these patients is mandatory [17,30]. 164 
Overall, although several guidelines regarding viral infections monitoring in 165 
immunocompromised patients are available, few address biological therapy. The 166 
appropriate serological tests are poorly defined, although evaluation of HBV status is 167 
widely supported, while HCV and HIV testing seems to be justified in high-risk patients. 168 
The European Crohn’s and Colitis Organisation consensus statement recommends 169 
universal testing (HBsAg, anti-HBs, anti-HBc) and HBV vaccination in all the patients with 170 
inflammatory bowel diseases, while no recommendations have been defined for HCV [31]. 171 
On the contrary, a consensus statement on pre-treatment testing in rheumatology patients 172 
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recommends the screening for HBV and HCV in all the patients, without a defined 173 
serological strategy [32].  174 
 175 
Anti-integrin VLA-4 176 
Natalizumab (Tysabri®) is a selective adhesion molecule inhibitor the target of which  is 177 
the α4 subunit of VLA-4 receptor. Natalizumab binds to α4-integrin expressed on the 178 
surface of activated T cells and other mononuclear leukocytes, where it prevents adhesion 179 
between the endothelial cell and the immune cell. This action inhibits the migration of 180 
leukocytes into the central nervous system. The main indication for natalizumab treatment 181 
is relapsing-remittent highly inflammatory multiple sclerosis (MS). However, the same 182 
mechanism of action implies a decreased local immune surveillance, thus possibly 183 
contributing to an increased risk of PML,                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           184 
a demyelinating disease caused by lytic replication of JCV in oligodendrocytes, that is 185 
observed in the setting of profound cellular immunosuppression, such as HIV patients and 186 
individuals exposed to potent antilymphocyte drugs, such as natalizumab, and other 187 
mAbs, such as rituximab and efalizumab. 188 
More than 30 PML cases have been reported worldwide in patients receiving natalizumab 189 
monotherapy for MS and data suggests that PML incidence increases with the number of 190 
infusions (increased risk after two years of therapy). Currently, ~30,000 patients treated or 191 
on treatment with natalizumab are being monitored for PML [12]. 192 
 193 
Conclusions  194 
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The elevated efficacy of mAbs is counterbalanced by an increased risk of infectious 195 
complications. The complete spectrum of viral diseases complicating their administration is 196 
still poorly known, although data are accumulating. Similarly, also virological screening and 197 
monitoring that should be performed in these patients are still undefined and vary largely 198 
depending on underlying disease, type of patients, and protocol. Particular attention is 199 
required for the monitoring of herpesviruses, JCV, HBV and HCV, and data that are being 200 
obtained could represent the basis to define consensus guidelines that take into account 201 
the evaluation of viral status pre-treatment, as well as viral replication/reactivation during 202 
therapy and following its interruption. The possible role played by the specific cellular 203 
immune response in containing viral replication remains to be determined and it is likely 204 
that viro-immunological monitoring could contribute to better understand the immunogical 205 
background underlying the occurrence of viral complications and to improve their clinical 206 
management. Overall, the role played by the virology laboratory is relevant as the basal 207 
evaluation of viral infection and the subsequent monitoring in patients treated  with 208 
biological agents could allow to start or continue a successful therapy in cases for which 209 
there are few treatment options. As the benefits of these agents outweigh their risks, the 210 
formulation of specific recommendations could allow to identify a small group of patients in 211 
which the treatment cannot be used or must be interrupted. The aim of developing specific 212 
recommendations and guidelines is becoming all the most important considering the 213 
growing utilization of these agents in different clinical contexts.   214 
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Table 1. Main viral infections/reactivations in patients undergoing monoclonal antibodies 306 
therapy and monitoring or recommendations. PTLD, post-transplantation 307 
lymphoproliferative disorders. 308 
 Anti-CD52 
(alentuzumab) 
Anti-CD20   
(rituximab) 
TNF-α antagonists 
(infliximab, 
etanercept, 
adalimumab, 
certolizumab pegol) 
Anti-integrin VLA-4 
(natalizumab) 
CMV 6-66% reactivation 
within 4-6 weeks, 
close monitoring (3,4) 
Few cases, close 
monitoring (5) 
Poorly known (22-26)  
HBV Active and prior 
infection as exclusion 
criteria in clinical trials 
20-55%, close 
monitoring (5,6-10) 
Case reports, close 
monitoring, exclusion 
criteria in clinical 
trials, but consider 
occult infection (18-
21) 
 
HCV Active and prior 
infection as exclusion 
criteria in clinical trials 
 Poorly known, close 
monitoring (14,15) 
 
VZV  Few cases (5) Poorly known (28)  
JCV  57 cases (11,12)  30 cases (12) 
EBV Up to 40% 
reactivation, <1% risk 
PTLD (33) 
 Poorly known (27)  
HPV   Poorly known (29)  
 309 
 310 
  311 
 312 
 313 
 314 
 315 
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Figure 1. Algorithm for the evaluation of viral infections in relation to the administration of 316 
alemtuzumab. 317 
Test CMV–DNA
before treatment  
with alemtuzumab
Negative 
Start alemtuzumab
and monitor CMV-
DNA weekly
Positive
Antiviral treatment 
to reduce viral load
to a non-detectable
level, then start 
alemtuzumab
Active or prior viral
hepatitis B or C or 
positive serological 
markers for HBV
No treatment with
alemtuzumab
HBsAb positive
Negative for HBsAg, 
HBcAb, anti-HCV 
Treatment with
alemtuzumab
Positive for HbsAg, 
HBcAb or anti-HCV
No treatment 
with alemtuzumb
 318 
